6808 Stock Overview
3D Global Biotech Inc. develops medical materials for human body reconstruction in China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
3D Global Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$33.15 |
| 52 Week High | NT$40.15 |
| 52 Week Low | NT$17.20 |
| Beta | 0.26 |
| 1 Month Change | -4.05% |
| 3 Month Change | 72.66% |
| 1 Year Change | 13.92% |
| 3 Year Change | -26.33% |
| 5 Year Change | n/a |
| Change since IPO | -34.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6808 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 3.1% | -1.1% | -0.6% |
| 1Y | 13.9% | -21.5% | 29.2% |
Return vs Industry: 6808 exceeded the TW Biotechs industry which returned -21.5% over the past year.
Return vs Market: 6808 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 6808 volatility | |
|---|---|
| 6808 Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6808's share price has been volatile over the past 3 months.
Volatility Over Time: 6808's weekly volatility has increased from 8% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 34 | n/a | www.3dglobalbiotech.com.tw |
3D Global Biotech Inc. develops medical materials for human body reconstruction in China. It uses cell culture systems, 3D printing technology, and bio-inks hydrogel as the basis to develop and produce customized autologous cell-based medical products. The company develops human tissue and organ reconstruction platforms; develops customized and personalized medical equipment; and conducts professional research.
3D Global Biotech Inc. Fundamentals Summary
| 6808 fundamental statistics | |
|---|---|
| Market cap | NT$2.21b |
| Earnings (TTM) | -NT$64.56m |
| Revenue (TTM) | NT$16.42m |
134.9x
P/S Ratio-34.3x
P/E RatioIs 6808 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6808 income statement (TTM) | |
|---|---|
| Revenue | NT$16.42m |
| Cost of Revenue | NT$12.36m |
| Gross Profit | NT$4.06m |
| Other Expenses | NT$68.62m |
| Earnings | -NT$64.56m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | 24.73% |
| Net Profit Margin | -393.11% |
| Debt/Equity Ratio | 0% |
How did 6808 perform over the long term?
See historical performance and comparison